Product
Recombinant new coronavirus vaccine (CHO cell)
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of AgeStatus: Completed, Estimated PCD: 2021-12-12